181 related articles for article (PubMed ID: 6327024)
1. A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines.
Cole SP; Campling BG; Louwman IH; Kozbor D; Roder JC
Cancer Res; 1984 Jul; 44(7):2750-3. PubMed ID: 6327024
[TBL] [Abstract][Full Text] [Related]
2. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
3. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.
Tong AW; Lee J; Stone MJ
Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal antibody to purified protein derivative of tuberculin produced by hybrids constructed with Epstein-Barr virus-transformed B lymphocytes and mouse myeloma cells.
Garzelli C; Puglisi C; Falcone G
Eur J Immunol; 1986 May; 16(5):584-7. PubMed ID: 3009205
[TBL] [Abstract][Full Text] [Related]
5. Human T cell hybridomas specific for Epstein Barr virus-infected B lymphocytes.
Lakow E; Tsoukas CD; Vaughan JH; Altman A; Carson DA
J Immunol; 1983 Jan; 130(1):169-72. PubMed ID: 6292301
[TBL] [Abstract][Full Text] [Related]
6. Generation of human anti-rubella monoclonal antibodies from human hybridomas constructed with antigen-specific Epstein-Barr virus transformed cell lines.
Hilfenhaus J; Kanzy EJ; Köhler R; Willems WR
Behring Inst Mitt; 1986 Jun; (80):31-41. PubMed ID: 3019293
[TBL] [Abstract][Full Text] [Related]
7. [Attempts to improve hybridoma technology for the production of human monoclonal antibodies].
Tokunaga T; Chiba J; Ohnishi K
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2198-204. PubMed ID: 3038035
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stable Epstein-Barr (EB) virus transformed cell lines and mouse-human hybridomas producing a large quantity of anti-tetanus toxoid (TT) monoclonal antibody.
Minakawa H; Hirata Y; Sugawara I; Fukuda A; Yoshida TO
Behring Inst Mitt; 1985 Dec; (78):139-47. PubMed ID: 3008706
[TBL] [Abstract][Full Text] [Related]
9. Analysis of human monoclonal antibodies derived from lymphocytes of patients with cancer.
Cote RJ; Morrissey DM; Oettgen HF; Old LJ
Fed Proc; 1984 Jun; 43(9):2465-9. PubMed ID: 6327400
[TBL] [Abstract][Full Text] [Related]
10. Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung.
Hanai N; Shitara K; Yoshida H
Cancer Res; 1986 Sep; 46(9):4438-43. PubMed ID: 3731100
[TBL] [Abstract][Full Text] [Related]
11. Human-human hybridomas generated with lymphocytes from patients with colorectal cancer.
Borup-Christensen P; Erb K; Jensenius JC; Svehag SE; Nielsen B
Cancer Detect Prev Suppl; 1987; 1():207-15. PubMed ID: 3480051
[TBL] [Abstract][Full Text] [Related]
12. Pokeweed mitogen-stimulated human lymphocytes fused to LICR-2 (HMY2) generate human-human hybridomas producing monoclonal IgG antibodies reactive to human breast carcinoma and malignant melanoma.
Martin RF; Kisor R; Schroer D; Eichler G; Filaccio ML
Hum Antibodies Hybridomas; 1990; 1(3):154-9. PubMed ID: 2103359
[TBL] [Abstract][Full Text] [Related]
13. Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells.
Doyle LA; Cuttitta F; Mulshine JL; Bunn PA; Minna JD
Cancer Res; 1987 Oct; 47(19):5009-13. PubMed ID: 3040237
[TBL] [Abstract][Full Text] [Related]
14. [A strategy for the production of human monoclonal antibodies].
Chiba J
Hum Cell; 1988 Mar; 1(1):31-6. PubMed ID: 2856441
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
[TBL] [Abstract][Full Text] [Related]
16. Renewal of EBV-hybridoma method: efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells.
Ainai A; Kawase T; Ida A; Maeda Y; Ohba H; Ikeda Y; Sato H; Takahashi M; Chiba J
Hum Antibodies; 2006; 15(4):139-54. PubMed ID: 17522436
[TBL] [Abstract][Full Text] [Related]
17. The hybridization of EBV-immortalized human B-lymphocytes with a human-mouse heteromyeloma cell line.
Jahn S; Walper A; Grunow R; Heym S; Volk HD; von Baehr R
Allerg Immunol (Leipz); 1990; 36(4):359-65. PubMed ID: 1965878
[TBL] [Abstract][Full Text] [Related]
18. Production of a human monoclonal antibody to HLA by human-human hybridoma technology. A preliminary report.
Hulette CM; Effros RB; Dillard LC; Walford RL
Am J Pathol; 1985 Oct; 121(1):10-4. PubMed ID: 2996358
[TBL] [Abstract][Full Text] [Related]
19. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
Epstein AL; Marder RJ; Winter JN; Fox RI
J Immunol; 1984 Aug; 133(2):1028-36. PubMed ID: 6376628
[TBL] [Abstract][Full Text] [Related]
20. SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus.
Gustafsson B; Jondal M; Sundqvist VA
Hum Antibodies Hybridomas; 1991 Jan; 2(1):26-32. PubMed ID: 1651784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
